Strategies for Treating Sexual Health Concerns After Breast and Gynecologic Cancer

A 30-year literature review on sexual dysfunction after cancer treatment applied no formal quality screen to the studies it included

Journal: Journal of Minimally Invasive Gynecology | Published: 2025-12-17 | Type: Journal Article, Review | PMID: 41419078 Authors: Mihulka O, Curran M, Narasimhan RM (University of Miami Miller School of Medicine); Moore JF (Women and Infants Hospital, Providence); Rojas KE (Sylvester Comprehensive Cancer Center, University of Miami) Funding/COI: Not listed

Summary

This is a narrative review covering three decades of literature on sexual dysfunction in breast and gynecologic cancer survivors, largely centered on genitourinary syndrome of menopause: vaginal dryness, dyspareunia, and low desire. The authors group nonhormonal options (moisturizers, lubricants, dilators, pelvic floor therapy) and selective local hormone therapy as reasonable, while flagging vaginal laser treatment and compounded hormones as risky. No original data is presented; it's a synthesis of prior work, not a primary study.

Claims

• Nonhormonal management (vaginal moisturizers, lubricants, dilators, pelvic floor therapy) is positioned as first-line for genitourinary syndrome of menopause symptoms
• Local hormonal therapy may help select patients, contingent on the hormone sensitivity of their specific cancer diagnosis
• Bremelanotide and flibanserin are cited as having demonstrated efficacy for low sexual desire, without effect sizes or trial data given
• Vaginal laser treatments and compounded hormone preparations are singled out as posing significant risk and are advised against
• Multidisciplinary coordination across gynecology, psychology, and oncology is presented as necessary for outcomes

Study Quality

This is a narrative review, not a systematic review or meta-analysis, despite searching PubMed, Google Scholar, and Scopus across 30 years of literature with defined search terms. The authors explicitly state "no formal quality assessment tool was applied" and instead relied on "emphasis... placed on high-impact studies and comprehensive reviews published in reputable journals" — a subjective standard that invites selection bias, since which studies count as "high-impact" or "reputable" is left to the authors' judgment rather than a reproducible instrument like AMSTAR or GRADE.

The exclusion criterion ("lacked methodological rigor") is similarly undefined in the abstract, meaning readers can't tell which studies were dropped or why. No sample sizes, effect sizes, or confidence intervals for any of the cited interventions (including bremelanotide and flibanserin) appear in the abstract, which limits how much weight the "demonstrated efficacy" language can bear without checking primary sources.

Red Flags

• No formal quality assessment tool applied to included studies, by the authors' own admission
• Funding source and conflicts of interest not disclosed
• Vague, non-reproducible inclusion/exclusion criteria ("lacked methodological rigor")
• No quantitative data (sample sizes, effect sizes) presented for any therapy discussed
• Thematic synthesis rather than systematic methodology, despite a broad 30-year search scope that implies more rigor than was applied

Strengths

• Multidisciplinary author team spanning gynecologic oncology and breast surgical oncology
• Addresses a genuinely underrecognized area: sexual dysfunction in cancer survivorship
• Draws a clear line between commonly recommended interventions and ones with real safety concerns (vaginal lasers, compounded hormones)
• Anchors hormone therapy discussion in cancer-specific hormone sensitivity, an important nuance this population needs

Verdict

This reads as a clinical primer for practitioners rather than rigorous evidence synthesis, and it says so itself: a literature review spanning 30 years with no formal quality assessment tool is a curated opinion piece dressed in review-article structure. The warning against vaginal lasers and compounded hormones is worth noting, but readers should treat the efficacy claims for named drugs and therapies as pointers to go check the primary literature, not as vetted conclusions.